Letting Go Biotech: Hardest Career Move

Letting go is the hardest career move in biotech because the industry trains you to bond with programs, teams, and missions that can disappear long before your work loses value. If you stay too attached to one company, one manager, or one molecule, you can lose time, leverage, and momentum when the business shifts.

Biotech rewards commitment, but it punishes rigidity. You need a way to read layoffs, manager exits, hiring slowdowns, and program resets without turning every company event into a verdict on your own worth. This article gives you that operating model, so you can make better career decisions when the science is strong but the organization is unstable.

Why Are Biotech Layoffs Still Happening?

Biotech layoffs keep happening because most companies in the sector are not built on stable cash flow. They run on funding, milestone timing, trial progress, and investor patience. When one of those breaks, leadership cuts headcount to preserve runway, narrow the pipeline, and keep the business alive long enough to reach the next value point.

If you work in biotech long enough, you stop reading layoffs as isolated events. You read them as capital allocation decisions. A company can have talented scientists, capable operators, a credible technology platform, and still cut teams when financing tightens, a lead asset stalls, or management decides to concentrate resources on fewer programs.

That is why layoffs in biotech often feel irrational from the bench or from a functional team. You may see productive people, useful projects, and clear effort. Leadership may see a burn rate problem, a delayed readout, a weak fundraising market, or a board that wants fewer bets. Those are different views of the same business, and the second one is usually the one that determines headcount.

You also need to separate company quality from company durability. A respected employer can still restructure. A promising platform company can still cut a quarter of its workforce. A large biopharma employer can still close sites, trim support functions, or reduce teams tied to deprioritized work. Once you accept that reality, you stop treating layoffs as rare disruptions and start treating them as part of biotech career planning.

The deeper issue is that drug development runs on long timelines and expensive failure. A team can do strong work for years and still lose its place when the asset no longer fits the portfolio. That is why letting go becomes a career skill. You are not just letting go of an employer. You are letting go of the assumption that effort alone protects your role.

Is Getting Laid Off Normal In Biotech, Or A Red Flag On Your Resume?

Getting laid off in biotech is normal enough that it usually does not damage your resume on its own. Hiring managers in this industry know the difference between a performance issue and a restructuring event. They understand that a company can remove entire functions, close programs, flatten layers of management, or cut excellent people after a financing setback.

What matters is not the layoff itself. What matters is how you explain the business event, what you delivered before it happened, and how cleanly you position the transition. If your story sounds defensive, vague, or emotional, you create doubt. If your story is direct and commercially literate, you sound experienced.

You need to talk about layoffs in biotech with the same clarity that executives use internally. State the trigger, state the impact, and state your contribution. A concise explanation works: the company reduced headcount after narrowing the pipeline, the function was cut after a strategic reset, the site changed priorities, the platform lost funding support. That language signals that you understand how biotech businesses work.

Resume risk enters the picture when short tenures pile up with no coherent thread. One layoff is normal. Two may still be normal. Several disconnected moves with weak explanations can make you look reactive. The fix is not to hide the pattern. The fix is to show continuity in your skills, your therapeutic area exposure, your stage experience, and the kinds of operational problems you solve.

You also gain leverage when you stop apologizing for market events you did not control. Many strong careers in biotech include layoffs, canceled programs, failed trials, acquisitions, site closures, and reorganizations. That does not weaken your profile if you can show progress through disruption. In this industry, steadiness is not measured by staying in one seat forever. It is measured by how well you hold value when the organization around you changes.

What Happens To A Biotech Team When A Strong Manager Is Let Go?

When a strong manager gets cut, the damage often spreads well beyond one title box on an organization chart. You lose decision speed, scientific memory, political cover, hiring judgment, and someone who knows how to translate leadership pressure into workable priorities. Teams feel that loss fast, even when leadership frames the move as a simple restructuring.

A strong manager in biotech is rarely just a task allocator. That person often protects the team from chaos, shapes realistic timelines, remembers failed experiments, and knows where the hidden operational risks sit. In discovery, translational work, process development, manufacturing, clinical operations, and regulatory work, that practical memory saves months. When it disappears, the team does not just lose support. It loses judgment.

You can usually spot the aftereffects within weeks. Communication gets thinner. Priorities get less coherent. Meetings become longer and less useful. People stop escalating problems early because trust drops. Teams begin to hold information closer, and high performers start taking recruiter calls. The company may not announce a morale problem, but you will feel one in how work moves.

The hardest version of this is when leadership replaces a respected manager with someone who lacks technical credibility or team trust. You then get a double hit: the old stabilizer is gone, and the new leader needs time the team does not have. In biotech, weak management is expensive because execution depends on cross-functional judgment, not just headcount.

If this happens around you, do not reduce the event to personal disappointment. Read it as a signal. Ask whether leadership cut a cost center, removed a dissenting voice, flattened the team for speed, or simply made a poor decision. The answer matters because it tells you whether the organization is getting sharper or less capable. That distinction should shape whether you stay, reposition, or leave.

Should You Stay After A Biotech Layoff, Or Leave Before The Next Round?

Staying after a layoff can be smart, but only when the company becomes more focused, better funded, and easier to read after the cuts. If the reorganization leaves the business confused, secretive, or visibly weaker, leaving early is often the better move. You should not measure the decision by loyalty. You should measure it by risk, timing, and role quality.

Start with the basic test: did leadership explain what changed in a way that makes business sense? A credible reset usually has a clear priority asset, a cleaner operating plan, and a believable case for runway. A weak reset sounds vague, spreads work across too many remaining teams, and avoids direct answers about headcount planning, cash, or program focus.

Your own role matters just as much as the company story. If you sit close to the asset, platform, or function that leadership now treats as essential, staying can expand your visibility and scope. You may pick up better work, stronger exposure, and tighter access to decision-makers. If your role sits near a deprioritized area, a support layer under pressure, or a site that looks vulnerable, your risk remains high no matter how reassuring leadership sounds.

You also need to assess the emotional drag. Many people stay after a layoff and underestimate how much the environment changes. Survivor guilt, mistrust, increased workload, and constant speculation can wear down good judgment. If you spend more energy interpreting signals than building useful work, the role is already costing you.

Do not wait for certainty. Biotech rarely offers it. Make the call based on direction. If the company is tightening around a real plan and your role is attached to it, staying can pay off. If the company is still cutting around the edges of the same unresolved problem, the safer move is to control your timing and search before the next wave strips away your leverage.

How Are Layoff Decisions Actually Made In Biotech?

Layoff decisions in biotech are usually made through a mix of runway math, pipeline priority, location strategy, and executive politics. Performance can matter, but it is often secondary to where leadership wants to place capital. That is why good people get cut and weaker people sometimes stay. The decision is often about role proximity to the next business milestone, not pure talent ranking.

If you want to understand a layoff, follow the asset. Ask which program is gaining resources, which one is being paused, and which teams support the company’s next financing or data event. Roles tied to a lead clinical program, a platform the company still believes can partner well, or a near-term regulatory milestone tend to survive longer. Roles tied to paused research, duplicated functions, optional workstreams, or slower bets get exposed first.

Management layers also matter. Companies under pressure often flatten organizations, remove middle managers, consolidate teams, and centralize decision-making. Site decisions can drive layoffs too. A company may favor one geography over another for cost, leadership presence, manufacturing access, or talent concentration. Those choices can remove excellent teams that happened to sit in the wrong place.

You should also understand that line managers do not always control the outcome. In many restructurings, decisions come down from the executive team after budget reviews, board discussions, or strategic planning exercises. Managers may be asked for input, but the broad shape is already set. That is why a supportive manager can still lose team members, and why a strong performance review does not guarantee safety when the company redraws its map.

This matters for your career because it changes how you interpret signals. If you think layoffs are mostly merit-based, you can internalize them in ways that slow recovery. If you understand that many layoffs are portfolio decisions, you can respond faster and with more precision. That does not make the event easier. It makes it more readable.

Is The Biotech Job Market Getting Better, Or Just More Competitive?

The biotech job market has shown signs of improvement, but it still feels crowded and selective for many professionals. You can see fewer layoffs in one slice of the market and more openings in another, yet still face longer searches, lower salary flexibility, and heavier competition for strong roles. Those things can all be true at the same time.

This is the part many people misread. A market can improve at the top line and still remain hard at the candidate level. Companies may post more jobs, but they can also narrow requirements, slow decision-making, and screen more aggressively. Candidates who are employed keep looking. Candidates who were cut stay in the market longer. That stacks more qualified people onto the same set of openings.

The pressure is especially visible in science and research roles. Those seats attract deep applicant pools, and many employers now expect closer matches in modality, therapeutic area, stage experience, and platform relevance. The broad career advice that worked in easier hiring cycles does less for you now. Generic resumes, vague networking, and passive applications do not move fast enough in a crowded field.

Compensation sends its own signal. When more candidates are willing to accept slower progression or lower cash to regain stability, employers gain leverage. Yet the market is not frozen. People who move into the right company at the right moment can still improve title, scope, and pay. The difference is that you need a tighter fit and a cleaner value case than before.

You should treat the current market as selective rather than broken. That stance is useful because it forces sharper career positioning. Target funded companies, priority functions, and roles close to value creation. Build a search around where capital is moving, not around where your old title seems transferable. In biotech, timing matters, but fit matters more when the market gets crowded.

What Should You Do In The First 30 Days After Being Let Go From A Biotech Job?

The first month after a layoff is not the time to drift. You need to stabilize the practical details fast, capture your work history while it is still fresh, and get back into the market before your own story starts to blur. The people who recover best in biotech do not move emotionally faster than everyone else. They move operationally faster.

Start with severance, benefits, equity, and access. Confirm what ends when, what paperwork matters, and which materials you can still retrieve legally and appropriately. Save performance reviews, nonconfidential work summaries, presentations you are allowed to keep, and any record of achievements that will help you rebuild your resume and interview narrative. Do that early, because memory decays and systems close.

Then build your market story. Write down the programs you supported, the modalities you touched, the stage of development, the tools you used, the decisions you influenced, and the measurable outcomes tied to your work. Translate internal language into external language. Hiring managers need to understand what you actually did without requiring insider knowledge of your former company.

Networking should begin quickly and with discipline. Reach out to former managers, colleagues, vendors, partners, investors, and recruiters who know your work directly. Do not send a generic note asking to chat. State the transition, define the kind of role you are targeting, and make it easy for people to place you. Strong biotech networks do not move because you are available. They move because they know where you fit.

You also need a company filter. Focus on funded employers, priority programs, revenue-linked functions, and teams that are hiring for growth rather than replacing attrition after cuts. Ask direct questions about runway, headcount plans, portfolio focus, and why the role is open. You are not just trying to get back in. You are trying to avoid walking into the same pattern with a different logo.

Emotion still matters, but it cannot run the plan. Layoffs can make smart people overcorrect. Some freeze. Some accept the first offer with a pulse. Some chase safety in a role that shrinks their future options. Better decisions come from sequence: stabilize, document, position, network, target, interview, evaluate. Keep the order tight and your recovery will be faster and cleaner.

Why Is Letting Go Harder In Biotech Than In Many Other Industries?

Letting go is harder in biotech because your work often feels larger than your employer. You are not just shipping a feature, managing a territory, or closing a quarter. You may be tied to a therapeutic idea, a platform technology, a patient promise, or a team built around years of technical effort. That creates a level of attachment that can outlast the company’s commitment to you.

The industry also attracts people who want mission and depth, not just employment. That is one of biotech’s strengths. It is also why career detachment can be so difficult. You can know intellectually that the company is cutting headcount for financial reasons and still feel as if the separation means your work, judgment, or commitment failed. That emotional mix keeps people in weak situations too long.

Another reason is that biotech work compounds through continuity. Teams develop tacit knowledge, shared technical language, and trust built through failed experiments, tight timelines, and difficult reviews. When you leave, you are not just losing a paycheck. You are losing an accumulated work environment where your value was legible. Rebuilding that somewhere else takes effort.

There is also identity risk. Many professionals in this industry quietly fuse personal worth with company mission, platform quality, scientific rigor, or proximity to respected leadership. When the company stumbles, they do not just lose role security. They lose the structure that helped them explain who they are professionally. That is why some of the hardest biotech transitions are not promotions or pivots. They are separations.

The fix is not emotional distance from the science. The fix is cleaner boundaries around the employer. You should care deeply about the work and still remain mobile, skeptical, and prepared. Once you learn that distinction, you protect your career without becoming cynical. That balance is what mature biotech professionals build over time.

How Do You Let Go Without Losing Momentum In Your Career?

You let go without losing momentum by shifting your loyalty from employer to capability. Companies can cut roles, cancel assets, replace managers, or sell the business. Your methods, judgment, network, and technical credibility travel with you. When you organize your career around those durable assets, transitions hurt less and recover faster.

That means tracking your value in a way many people neglect when they are busy. Keep a live record of achievements, tools, assays, systems, submissions, audits, process improvements, team leadership, and business outcomes. Maintain relationships before you need them. Build a resume that can be updated in hours, not weeks. Stay aware of who is hiring in your modality, therapeutic area, and function even when you are not actively looking.

It also means refusing to confuse endurance with strength. Staying through chaos can be useful when the company has a real plan and your role gains strategic weight. Staying through denial, secrecy, and repeated drift usually drains your market value. You need the discipline to leave a story that no longer serves your career, even when the science still appeals to you.

Strong professionals also reset their language. They do not say they were blindsided forever, even if they were. They learn the business explanation, sharpen the resume explanation, and move into the next conversation with control. That is not spin. That is executive maturity. People trust candidates who understand what happened around them.

Career momentum in biotech comes from repeated repositioning toward funded work, meaningful scope, and credible leadership. Letting go is painful when you think it means losing progress. It becomes manageable when you treat it as redeployment. The work you did still counts. Your next move determines whether you convert it into range or let it sit as history.

What Should You Do After A Biotech Layoff?

Secure severance, benefits, and equity details.
Document achievements, programs, and technical scope.
Activate trusted contacts with a clear target role.
Focus on funded companies and priority assets.
Explain the layoff as a business event, not a personal failure.

Make Your Next Move Before The Company Makes It For You

The hardest career move in biotech is letting go because the industry rewards commitment right up to the point where the business no longer supports the work. If you want a durable career, you need to read layoffs, manager exits, and strategic resets as signals, not shocks. That lets you protect your timing, sharpen your story, and move toward companies where your work has a clearer future. The goal is not detachment from science or ambition. The goal is disciplined attachment to your own value, so when a company changes course, your career does not stall with it.

References

Nirdosh Jagota

Nirdosh Jagota is Managing Partner at GRQ Biotech Advisors with 30+ years in the biotech industry. A former executive at Amgen, Genentech/Roche, Merck, and Pfizer, he has led >25 NDAs/BLAs/MAAs and hundreds of INDs across global regulatory, quality, and compliance.

The Hardest Career Move in Biotech Is Letting Go